FDA Green Lights Bizengri Drug To Treat Rare, Aggressive Bile Duct Cancer

Follow Drugslib on

By Andria Park Huynh HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 11, 2026.

via HealthDay

MONDAY, May 11, 2026 — The U.S. Food and Drug Administration (FDA) has approved Bizengri to treat an ultra-rare, aggressive cancer that forms in the bile ducts.

Bizengri (zenocutuzumab-zbco) is the first drug approved for adults with advanced, inoperable or metastatic cholangiocarcinoma with NRG1 gene fusion, the FDA announced.

NRG1, or neuregulin 1, gene fusions occur when two parts of a cell's DNA join together (or fuse) – an action that signals cells to grow abnormally, according to the American Lung Association. This leads to the growth of cancer cells.

Friday’s approval follows the FDA's 2024 approval for Bizengri to treat adults with advanced, metastatic or inoperable non-small cell lung cancer and pancreatic cancer.

Cholangiocarcinoma has been a clinical challenge, according to Cleveland Clinic, with inadequate, and largely ineffective, options for those battling the disease after initial treatment.

Last week’s approval is the seventh granted under the Commissioner’s National Priority Voucher (CNPV) pilot program for accelerated drug review and approval.

“Patients with this ultra-rare type of cancer desperately need new treatment options,” FDA Commissioner Dr. Marty Makary said in a news release. “Through the national priority voucher pilot program, the FDA is accelerating therapies for rare diseases with unmet medical needs, reviewing applications in significantly shortened timelines."

In one trial of 19 adults with NRG1 fusion-positive cholangiocarcinoma, 37% responded to the drug. The length of response ranged from about three months to 13, according to the FDA.

Serious side effects associated with Bizengri include infusion-related reactions, interstitial lung disease or pneumonitis, as well as left ventricular dysfunction, a condition in which the heart is unable to pump blood effectively to the body.

More common side effects include aches, digestive upsets, fatigue and edema.

The FDA granted the approval to Partner Therapeutics, Inc.

Sources

  • U.S. Food and Drug Administration, news release, May 8, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-05-12 02:42

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords